AI tools can now generate working software in minutes. A founder can describe an idea, press enter, and get a prototype the same day. The speed feels revolutionary, but many teams hit the same wall a few weeks later: the code works in a demo but breaks under real-world circumstances.

Seventy percent of companies are testing AI, yet fewer than one in three see real financial returns. Many teams start with excitement and end with a stalled pilot, unclear ROI, or a system that works in a demo but fails in production.

More than 80% of enterprises are expected to use generative AI in production by 2026. Yet many AI initiatives still stall before they deliver measurable value. Budgets are approved, models are tested, and demos look impressive. But once exposed to real users, the results often fall short.

Speed is one of the most misunderstood goals in healthcare software. Teams adopt FHIR, pick a modern platform, expect momentum, and… stall when compliance, access control, and operations surface late.

A single missed vulnerability can turn into a breach costing millions, but not every security issue needs the same kind of testing. Teams often struggle to decide where to focus: continuous automation or deep, manual validation.

AI budgets are rising fast. Global AI spending is expected to pass $500 billion within the next few years, yet most organizations still struggle to turn pilots into real business value. Many projects stall. Some never reach production. Others launch but fail to scale.
